6u4u

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
==1.3 A structure of a pathogenic human Syt 1 C2B (I368T)==
==1.3 A structure of a pathogenic human Syt 1 C2B (I368T)==
-
<StructureSection load='6u4u' size='340' side='right'caption='[[6u4u]]' scene=''>
+
<StructureSection load='6u4u' size='340' side='right'caption='[[6u4u]], [[Resolution|resolution]] 1.30&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6U4U OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6U4U FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[6u4u]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6U4U OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6U4U FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6u4u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6u4u OCA], [http://pdbe.org/6u4u PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6u4u RCSB], [http://www.ebi.ac.uk/pdbsum/6u4u PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6u4u ProSAT]</span></td></tr>
+
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
 +
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1uow|1uow]]</td></tr>
 +
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">SYT1, SVP65, SYT ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6u4u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6u4u OCA], [http://pdbe.org/6u4u PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6u4u RCSB], [http://www.ebi.ac.uk/pdbsum/6u4u PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6u4u ProSAT]</span></td></tr>
</table>
</table>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/SYT1_HUMAN SYT1_HUMAN]] May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse. It binds acidic phospholipids with a specificity that requires the presence of both an acidic head group and a diacyl backbone. A Ca(2+)-dependent interaction between synaptotagmin and putative receptors for activated protein kinase C has also been reported. It can bind to at least three additional proteins in a Ca(2+)-independent manner; these are neurexins, syntaxin and AP2.
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
At neuronal synapses, synaptotagmin-1 (syt1) acts as a Ca(2+) sensor that synchronizes neurotransmitter release with Ca(2+) influx during action potential firing. Heterozygous missense mutations in syt1 have recently been associated with a severe but heterogeneous developmental syndrome, termed syt1-associated neurodevelopmental disorder. Well-defined pathogenic mechanisms, and the basis for phenotypic heterogeneity in this disorder, remain unknown. Here, we report the clinical, physiological, and biophysical characterization of three syt1 mutations from human patients. Synaptic transmission was impaired in neurons expressing mutant variants, which demonstrated potent, graded dominant-negative effects. Biophysical interrogation of the mutant variants revealed novel mechanistic features concerning the cooperative action, and functional specialization, of the tandem Ca(2+)-sensing domains of syt1. These mechanistic studies led to the discovery that a clinically approved K(+) channel antagonist is able to rescue the dominant-negative heterozygous phenotype. Our results establish a molecular cause, basis for phenotypic heterogeneity, and potential treatment approach for syt1-associated neurodevelopmental disorder.
 +
 +
Molecular Basis for Synaptotagmin-1-Associated Neurodevelopmental Disorder.,Bradberry MM, Courtney NA, Dominguez MJ, Lofquist SM, Knox AT, Sutton RB, Chapman ER Neuron. 2020 Apr 21. pii: S0896-6273(20)30272-5. doi:, 10.1016/j.neuron.2020.04.003. PMID:32362337<ref>PMID:32362337</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 6u4u" style="background-color:#fffaf0;"></div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
 +
[[Category: Human]]
[[Category: Large Structures]]
[[Category: Large Structures]]
-
[[Category: Bradberry MM]]
+
[[Category: Bradberry, M M]]
-
[[Category: Chapman ER]]
+
[[Category: Chapman, E R]]
-
[[Category: Dominguez MJ]]
+
[[Category: Dominguez, M J]]
-
[[Category: Sutton RB]]
+
[[Category: Sutton, R B]]
 +
[[Category: C2 domain]]
 +
[[Category: C2b]]
 +
[[Category: Exocytosis]]
 +
[[Category: Greek key]]

Revision as of 11:35, 22 July 2020

1.3 A structure of a pathogenic human Syt 1 C2B (I368T)

PDB ID 6u4u

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools